(BUSINESS WIRE)–Jan. 21, 2015– Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, February 10, 2015 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Telephone 888-438-5525 (domestic) or 719-457-2085 (international);… Read more »
Shares of Seattle Genetics closed yesterday at $31.72 . SGEN has a 1-year high of $55.99 and a 1-year low of $30.05. The stock’s 50-day moving average is $32.81 and it’s 200-day moving average is $36.59.
On the ratings front, Seattle Genetics has been the subject of a number of recent research reports. In a report published on December 8, analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on SGEN, with a price target of $65, which implies an upside of 104.9% from current levels. Separately, on the same day, Cowen`s Boris Peaker reiterated a Hold rating on Seattle Genetics shares and has a price target of $34.
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.